In VivoThe treatment landscape for atopic dermatitis has undergone a transformation in the last seven years, spurred largely by the launch of Sanofi and Regeneron’s blockbuster IL-4/IL-13 inhibitor Dupixent
ScripPharma Breaks Bread With Trump And RFK Jr But Will They Butt Heads? Donald Trump’s second term as US president does not begin until 20 January but pharma executives spent much of last year wondering w
ScripThe treatment landscape for atopic dermatitis has undergone a transformation in the last seven years, spurred largely by the launch of Sanofi and Regeneron’s blockbuster IL-4/IL-13 inhibitor Dupixent
ScripThere were a few jitters as its target date of 7 July came and went but Arcutis Biotherapeutics, Inc. can breathe easy after the firm's topical skin formulation Zoryve received US approval for atopi